# US 2022/0016028 A1 · Topical montelukast formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016028 A1
- Document ID: US20220016028A1
- Status: Published application
- Kind: A1
- Application number: 17/489,516
- Filed: 2021-09-29
- Published: 2022-01-20
- Earliest claimed: 2020-02-03
- Assignees: Taro Pharmaceutical Industries Ltd.
- Applicants: Taro Pharmaceutical Industries Ltd.
- Inventors: Vered ROSENBERGER; Helena SHIFRIN; Irena OLEINIK; Tzviel SHESKIN; Ron SCHLINGER; Avi AVRAMOFF
- Web page: https://patentgrep.com/patent/US20220016028A1

## CPC

- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/47: Quinolines; Isoquinolines
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/08: Antiseborrheics
- A61P 17/10: Anti-acne agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

## Claims

### Claim 1

A topical emulsion comprising
a. about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof and
b. about 0.4% to about 4% carbomer;
wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.

### Claim 2 (depends on 1)

The topical emulsion of claim 1, wherein the particles have D50 of less than about 30 μm.

### Claim 3 (depends on 1)

The topical emulsion of claim 1, wherein the average particle size of the particles does not change greater than 10% over a period of 3 months at 25° C.

### Claim 4 (depends on 1)

The topical emulsion of claim 1, wherein the emulsion comprises about 4% to about 8% Montelukast.

### Claim 5 (depends on 1)

The topical emulsion of claim 1, wherein the emulsion comprises about 40% to about 70% water.

### Claim 6 (depends on 1)

The topical emulsion of claim 1, wherein the emulsion comprises less than 10% alcohol.

### Claim 7 (depends on 1)

The topical emulsion of claim 1, wherein the emulsion comprises less than 2% C1-C5 alcohol.

### Claim 8 (depends on 1)

The topical emulsion of claim 1, further comprising a preservative, an amphiphilic compound, an emulsifier, a lubricant, or combinations thereof.

### Claim 9 (depends on 8)

The topical emulsion of claim 8, wherein the preservative is an antioxidant.

### Claim 10 (depends on 9)

The topical emulsion of claim 9, wherein the antioxidant comprises BHT, BHA or combinations thereof.

### Claim 11 (depends on 8)

The topical emulsion of claim 8, wherein the amphiphilic compound comprises, oleyl alcohol, polyoxyglycerides, propylene carbonate, propylene glycol, or combinations thereof.

### Claim 12 (depends on 11)

The topical emulsion of claim 11, wherein the amphiphilic compound is propylene glycol.

### Claim 13 (depends on 8)

The topical emulsion of claim 8, wherein the emulsifier is a polysorbate.

### Claim 14 (depends on 8)

The topical emulsion of claim 8, wherein the lubricant is polypropylene glycol stearyl ether.

### Claim 15 (depends on 1)

The topical emulsion of claim 1, wherein the total impurities in the emulsion is less than 2% after 12 months at 25° C.

### Claim 16 (depends on 1)

The topical emulsion of claim 1, wherein the sulfoxide impurity in the emulsion is less than 2% after 12 months at 25° C., wherein the cis-isomer impurity in the emulsion is less than 1% after 12 months at 25° C., and/or wherein the methylstyrene impurity in the emulsion is less than 0.2% after 12 months at 25° C.

### Claim 17 (depends on 1)

The topical emulsion of claim 1, wherein the emulsion has a maximum globule size of less than about 100 μm.

### Claim 18 (depends on 1)

The topical emulsion of claim 1, wherein the emulsion has a maximum globule size of less than about 20 μm.

### Claim 19 (depends on 1)

A method of treating atopic dermatitis, erythema, pruritus or combinations thereof comprising administering the topical emulsion of claim 1.

### Claim 20

A method of treating atopic dermatitis, erythema, pruritus or combinations thereof comprising topically administering a stable formulation comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof, wherein the formulation is stable for at least 2 weeks.

### Claim 21

A method of reducing IGA score or BSA score in a subject suffering from atopic dermatitis, the method comprising topically administering to the subject a Montelukast formulation comprising at least 1% (wt/wt) Montelukast or pharmaceutically acceptable salt thereof for at least 10 days, wherein the IGA score or the BSA score is reduced by at least 5% from placebo.

### Claim 22

A stable topical formulation comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; wherein the total impurities resulting from the degradation of Montelukast in the composition is less than 2% after 6, 12, 24 or 36 months.

### Claim 23 (depends on 22)

The stable topical formulation of claim 22, wherein the sulfoxide impurity in the formulation is less than 2% after 12, 24 or 36 months at 25° C. and 60% humidity.

### Claim 24 (depends on 22)

The stable topical formulation of claim 22, wherein the cis-isomer impurity in the formulation is less than 1% after 12, 24 or 36 months at 25° C. and 60% humidity.

### Claim 25 (depends on 22)

The stable topical formulation of claim 22, wherein the methylstyrene impurity in the formulation is less than 0.2% after 12, 24 or 36 months at 25° C. and 60% humidity.

### Claim 26 (depends on 22)

The stable topical formulation of claim 22 wherein the total impurities resulting from the degradation of Montelukast in the composition is less than 2% after 6 months at 40° C. and 75% humidity.

### Claim 27 (depends on 26)

The stable topical formulation of claim 26, wherein the sulfoxide impurity in the formulation is less than 2% after 6 months at 40° C. and 75% humidity.

### Claim 28 (depends on 26)

The stable topical formulation of claim 26, wherein the cis-isomer impurity in the formulation is less than 1% after 6 months at 40° C. and 75% humidity.

### Claim 29 (depends on 26)

The stable topical formulation of claim 26, wherein the methylstyrene impurity in the formulation is less than 0.2% after 6 months at 40° C. and 75% humidity.
